Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

In Depth 21 Mar 2017

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]

March 21, 2017 - 7 minutesmins - By Evelyn Warner

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

BenevolentAI Artificial Intelligence Fundraising

Interview 20 Mar 2017

Machines are Helping Healthcare: An Interview with their Biotech Leader

BenevolentAI is leading the charge in artificial intelligence. We talked to Jackie Hunter, who is the CEO of the company’s bioscience arm, BenevolentBio. Jackie Hunter has had quite an impressive career! After defending her PhD in psychology, she transitioned to GSK, where she clocked nearly 20 years in various leadership positions — Director while the […]

March 20, 2017 - 8 minutesmins - By Evelyn Warner

Interview 13 Mar 2017

Infographic: The Microbiome Market & Research by the Numbers

A new infographic from Intellisness describes global therapeutic efforts in the microbiome through target indications, investment and patents. Image from freedomnaruk / shutterstock.com

March 13, 2017 - 1 minutemin - By Evelyn Warner

Interview 13 Mar 2017

Meet the Omics Entrepreneur who also Co-Founded EMBL

If you haven’t heard of Kai Simons, his mile-long list of accomplishments will make you wonder why. He told us some of what he learned along the way. Our Head of Business Development, Tom, was on the train from Paris to Lille for an intense day of sales meetings when he pulled up the bio […]

March 13, 2017 - 7 minutesmins - By Evelyn Warner

Interview 8 Mar 2017

International Women’s Day: An Infographic on Gender Diversity in Biotech

Today we celebrate women and promote a more gender-inclusive industry. Biotech is infamous for its divide, but what are the numbers? Whether it’s launching the next generation of insulin or running the business arm of one of Europe’s leading immuno-oncology biotechs, women have made major strides in biotechnology as some prominent leaders on the scene. “I […]

March 8, 2017 - 3 minutesmins - By Evelyn Warner

Interview 6 Mar 2017

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made a splashy debut in 2014 with a €25M fundraising round, only to outdo it with a €1B deal with AstraZeneca last fall. What’s the fuss? […]

March 6, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 2 Mar 2017

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]

March 2, 2017 - 5 minutesmins - By Evelyn Warner

Interview 27 Feb 2017

Meet the Woman developing the Next Generation of Insulin

Fiasp, ultra-fast-acting insulin, could revolutionize insulin. We chatted with Liselotte Hyveled, the woman heading the team behind it. “I didn’t get into nursing school, so I went into pharmacy instead,” Liselotte Hyveled laughs. “In Denmark, we have free education, but the government limits degrees for students based on job market needs. There was a low […]

February 27, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 24 Feb 2017

What are the Current Challenges in the Booming Field of ADCs?

ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the World ADC Conference to hear about current efforts. ADCs represent an exciting new field that has seen renewed interest in the past few months, as funding has poured into NBE Therapeutics and ADC Therapeutics. Theses drugs are overcoming the challenges that held the first two generations back […]

February 24, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 23 Feb 2017

In the Age of Biological Therapeutics, Chemists move to ADCs

Career options for chemists are shrinking in the shift towards biological drugs. But as antibody-drug conjugates (ADCs) take off, so do opportunities for chemists! Since I quit graduate school in chemistry research and dove into biotech journalism, I wasn’t sure when I would next enter a discussion about organic synthesis. This week, less than a year after […]

February 23, 2017 - 4 minutesmins - By Evelyn Warner

Russ Cummings Touchstone Innovations Edited e1487839162471

Interview 20 Feb 2017

Investment CEO shares Tips for Academics on Succeeding in Business

With decades of experience, the CEO of Touchstone Innovations tells us about funding the development of academic projects into commercialized products Formerly known as Imperial Innovations, the investing arm of Imperial College in London has since morphed into Touchstone Innovations, an UK technology commercialization and investment company with the same core mission in bridging the gap […]

February 20, 2017 - 7 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us